Další formáty:
BibTeX
LaTeX
RIS
@article{1746196,
author = {Pelletier, J. P. and Raynauld, J. P. and Dorais, M. and Bessette, L. and Dokoupilová, Eva and Morin, F. and Pavelka, K. and Paiement, P. and MartelandPelletier, J.},
article_location = {OXFORD},
article_number = {12},
doi = {http://dx.doi.org/10.1093/rheumatology/keaa072},
keywords = {diacerein; celecoxib; osteoarthritis; non-inferiority trial; SYSADOA},
language = {eng},
issn = {1462-0324},
journal = {RHEUMATOLOGY},
title = {An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis},
url = {https://pubmed.ncbi.nlm.nih.gov/32521015/},
volume = {59},
year = {2020}
}
TY - JOUR
ID - 1746196
AU - Pelletier, J. P. - Raynauld, J. P. - Dorais, M. - Bessette, L. - Dokoupilová, Eva - Morin, F. - Pavelka, K. - Paiement, P. - Martel-Pelletier, J.
PY - 2020
TI - An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis
JF - RHEUMATOLOGY
VL - 59
IS - 12
SP - 3858-3868
EP - 3858-3868
PB - OXFORD UNIV PRESS
SN - 14620324
KW - diacerein
KW - celecoxib
KW - osteoarthritis
KW - non-inferiority trial
KW - SYSADOA
UR - https://pubmed.ncbi.nlm.nih.gov/32521015/
N2 - Objective. The objective of this study was to investigate whether diacerein has comparable efficacy with celecoxib in pain reduction for treatment in symptomatic knee OA patients. Methods. This randomized double-blind multicentre non-inferiority trial evaluated diacerein vs celecoxib treatment in patients with Kellgren-Lawrence grade 2-3 and pain scoring >= 4 (10-cm VAS). Patients were randomized to 6 months of treatment with diacerein 50 mg (n = 1 87) once daily for 1 month and twice daily thereafter, or celecoxib 200mg (n =193) once daily. The primary outcome was the change in WOMAC pain score (0-50 cm) at 6 months, and the secondary outcomes were WOMAC sub-scores, VAS pain score, and the OMERACT-OARSI responder rate. Results. In the per protocol population, the adjusted mean change from baseline in the WOMAC pain score was -11.1 (0.9) with diacerein (n = 1 40) and -11.8(0.9) with celecoxib (n = 1 48). The intergroup difference was 0.7 (95% CI: -1.8, 3.2; P = 0.597), meeting the non-inferiority margin. Supportive analysis of the intention-to-treat population gave similar results. Other outcomes showed no significant difference between treatment groups. The incidence of treatment-related adverse events was low and balanced between groups, but a greater incidence of diarrhoea occurred with diacerein (10.2% vs 3.7%). Diarrhoea was considered mild-to-moderate in all but one case with complete resolution. Conclusions. Diacerein was non-inferior to celecoxib in reducing knee OA pain and improving physical function. Diacerein also demonstrated a good safety profile.
ER -
PELLETIER, J. P., J. P. RAYNAULD, M. DORAIS, L. BESSETTE, Eva DOKOUPILOVÁ, F. MORIN, K. PAVELKA, P. PAIEMENT a J. MARTEL-PELLETIER. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. \textit{RHEUMATOLOGY}. OXFORD: OXFORD UNIV PRESS, 2020, roč.~59, č.~12, s.~3858-3868. ISSN~1462-0324. Dostupné z: https://dx.doi.org/10.1093/rheumatology/keaa072.
|
